FDA
FDA Articles
PTC Therapeutics saw its shares jump late Friday morning on positive news on its nonsense mutation Duchenne muscular dystrophy treatment.
Published:
Last Updated:
inVentiv has filed with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
Regeneron Pharmaceuticals has announced that two Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe atopic dermatitis met their...
Published:
Last Updated:
Opko Health saw its shares slide in Wednesday’s regular trading session following the release of a complete response letter from the FDA.
Published:
Last Updated:
Acadia Pharmaceuticals saw its shares on the rise again this week following an incredibly positive FDA vote on its Parkinson's treatment.
Published:
Last Updated:
The SEC has announced fraud charges against Aveo Pharmaceuticals and three former executives for misleading investors.
Published:
Last Updated:
Inovio Pharmaceuticals made waves early on Tuesday morning following an update for its human papillomavirus (HPV) treatment.
Published:
Last Updated:
FDA rulings can make or break some companies. 24/7 Wall St. has collected eight key FDA decisions coming up in 2016 or 2017.
Published:
Last Updated:
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) surged early on Monday morning. This company is under the spotlight by the U.S. Food and Drug Administration’s Psychopharmacologic Drugs...
Published:
Last Updated:
Alder Biopharmaceuticals announced positive top-line data from two clinical trials evaluating its proprietary monoclonal antibody product candidate for migraine prevention.
Published:
Last Updated:
Clearside Biomedical has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
Published:
Last Updated:
BioMarin Pharmaceutical made waves early Monday following the release of late-stage results from its pegvaliase study.
Published:
Last Updated:
24/7 Wall St. has collected a few more U.S. Food and Drug Administration (FDA) decisions coming up in March.
Published:
Last Updated:
Celator Pharmaceuticals has announced positive results from its Phase 3 trial of Vyxeos Liposome for Injection in patients with high-risk (secondary) acute myeloid leukemia.
Published:
Last Updated:
One analyst firm believes the development of abuse-deterrent formulations (ADF) of opioids creates a risk that older non-ADFs may be removed from the market, creating a huge risk and opportunity in...
Published:
Last Updated: